We are live on ! Find out more
FIA

FNY Investment Advisers Portfolio holdings

AUM $278M
1-Year Est. Return 98.99%
This Fund
S&P 500
This Quarter Est. Return
+9.23%
1 Year Est. Return
+98.99%
3 Year Est. Return
+307.32%
5 Year Est. Return
+396.61%
10 Year Est. Return
AUM
$78.9M
AUM Growth
-$8.45M
Cap. Flow
-$8.23M
Cap. Flow %
-10.43%
Top 10 Hldgs %
39.35%
Holding
803
New
189
Increased
92
Reduced
66
Closed
232

Sector Composition

Rank Sector Weight
1 Healthcare 26.37%
2 Technology 14.3%
3 Industrials 13.87%
4 Consumer Discretionary 7.56%
5 Materials 6.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BREZR
726
DELISTED
Breeze Holdings Acquisition Corp. Right
BREZR
$0 ﹤0.01%
300
OPGN
727
DELISTED
OpGen, Inc
OPGN
-5,089
Closed -$67K
AEL
728
DELISTED
American Equity Investment Life Holding Company
AEL
-1,000
Closed -$36K
CASA
729
DELISTED
Casa Systems, Inc. Common Stock
CASA
-5,043
Closed -$6K
AYX
730
CALL
DELISTED
Alteryx Inc
AYX
-50
Closed -$2K
FTCH
731
DELISTED
Farfetch Limited Class A Ordinary Shares
FTCH
-1,017
Closed -$4K
KVSA
732
DELISTED
Khosla Ventures Acquisition Co. Class A Common Stock
KVSA
-133,950
Closed -$1.36M
CFIVU
733
DELISTED
CF Acquisition Corp. IV Unit
CFIVU
$0 ﹤0.01%
+9
New +$94
PACW
734
CALL
DELISTED
PacWest Bancorp
PACW
-300
Closed -$2K
JHAA
735
DELISTED
Nuveen Corporate Income 2023 Target Term Fund
JHAA
$0 ﹤0.01%
50
NEWR
736
DELISTED
New Relic, Inc.
NEWR
-2,100
Closed -$158K
DEN
737
DELISTED
Denbury Inc.
DEN
-1,500
Closed -$131K
CANO
738
DELISTED
Cano Health, Inc.
CANO
-1
Closed
CCV.WS
739
DELISTED
Churchill Capital Corp V Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share
CCV.WS
$0 ﹤0.01%
4,750
NATI
740
DELISTED
National Instruments Corp
NATI
-5,000
Closed -$287K
RETA
741
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
-15
Closed -$1K
RBT
742
DELISTED
Rubicon Technologies, Inc.
RBT
-1,686
Closed -$8K
NUVA
743
DELISTED
NuVasive, Inc.
NUVA
-1,200
Closed -$49K
IDEX
744
DELISTED
Ideanomics, Inc. Common Stock
IDEX
-4
Closed
REUN
745
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
-28,050
Closed -$19K
AJRD
746
DELISTED
Aerojet Rocketdyne Holdings
AJRD
-40
Closed -$2.22K
XM
747
DELISTED
Qualtrics International Inc. Class A Common Stock
XM
-140
Closed -$2K
NIQ
748
DELISTED
NUVEEN INTERMEDIATE DURATION QUALITY MUNICIPAL TERM FUND
NIQ
-100
Closed -$1K
GTXAP
749
DELISTED
Garrett Motion Inc. Series A Cumulative Convertible Preferred Stock
GTXAP
-160
Closed -$1K
STSA
750
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
-46,187
Closed -$32K

Similar funds

FNY Investment Advisers's Q2 2023 Portfolio in Review

As of Q2 2023, FNY Investment Advisers held 803 positions worth $78.9M, down 9.7% from $87.4M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

FNY Investment Advisers withdrew a net $8.23M in Q2 2023, closing 232 positions and reducing 66 holdings. Its most notable exit was Oak Street Health, Inc., an estimated $8.19M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 23% a quarter earlier, followed by Technology and Industrials.

Against the trend, FNY Investment Advisers opened a new position in IVERIC bio, Inc. Common Stock worth $7.08M.

  • FNY Investment Advisers's largest Q2 2023 buy was IVERIC bio, Inc. Common Stock: 180,106 shares worth $7.08M.
  • FNY Investment Advisers added most to Univar Solutions Inc. in Q2 2023, an estimated $1.85M increase.
  • FNY Investment Advisers's biggest Q2 2023 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $1.53M.
  • FNY Investment Advisers fully exited Oak Street Health, Inc. in Q2 2023, selling an estimated $8.19M.
  • FNY Investment Advisers's ten largest holdings make up 39% of its $78.9M portfolio in Q2 2023.
  • FNY Investment Advisers opened 189 new positions and closed 232 in Q2 2023.
  • FNY Investment Advisers's portfolio value fell 9.7% quarter-over-quarter to $78.9M.

Based on FNY Investment Advisers's 13F filing for Q2 2023, filed 11 Jul 2023.